SARASOTA, Fla., June 20, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it received a notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) dated June 18, 2024, notifying the Company that it has accepted the Company’s plan to regain compliance with NYSE American’s continued listing standards..

佛罗里达州萨拉索塔，2024年6月20日（环球通讯社）--专注于开发用于治疗神经系统疾病的独特鼻内药物的Oragenics，Inc.（纽约证券交易所美国代码：OGEN）公司今天宣布，它收到了纽约证券交易所美国公司（“纽约证券交易所美国公司”）于2024年6月18日发出的通知（“通知”），通知该公司已接受该公司重新遵守纽约证券交易所美国公司继续上市标准的计划。。

The NYSE American has reviewed Oragenics’ compliance plan and information submitted on May 17, 2024, and determined that the Company made a reasonable demonstration of its ability to make substantial progress toward regaining compliance by October 18, 2025. During this time, the Company will be subject to quarterly monitoring for compliance with the plan.

纽约证交所美国证券交易所（NYSE American）审查了Oragenics于2024年5月17日提交的合规计划和信息，并确定该公司已合理证明其有能力在2025年10月18日之前在恢复合规方面取得实质性进展。在此期间，公司将接受季度监测，以确保其遵守计划。

If the Company does not regain compliance with NYSE American’s listing standards by October 18, 2025, or if the Company does not make sufficient progress consistent with its plan, then the NYSE American may initiate delisting proceedings at that time..

如果公司在2025年10月18日之前没有重新符合纽约证券交易所美国上市标准，或者公司没有取得与其计划一致的足够进展，那么纽约证券交易所美国上市公司可能会在那时启动退市程序。。

About Oragenics

关于Oragenics

Oragenics is a development-stage biotechnology company focused on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI), also known as concussion, and for treating Niemann Pick Disease Type C (NPC), as well as proprietary powder formulation and an intranasal delivery device.

Oragenics是一家处于发展阶段的生物技术公司，专注于神经病学和抗击传染病中药物的鼻腔给药，包括用于治疗轻度创伤性脑损伤（mTBI）（也称为脑震荡）和治疗C型尼曼-匹克病（NPC）的候选药物，以及专有的粉末制剂和鼻内给药装置。

For more information, please visit www.oragenics.com..

有关更多信息，请访问www.oragenics.com。。

Forward-Looking Statements

前瞻性声明

This communication contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including with regard to the Company’s ability to regain compliance with the NYSE American’s continued listing standards by October 18, 2025.

本通讯包含1995年《美国私人证券诉讼改革法案》安全港条款所指的“前瞻性声明”，包括关于公司在2025年10月18日之前重新遵守纽约证券交易所美国公司持续上市标准的能力。

These forward-looking statements are based on management’s beliefs and assumptions and information currently available. The words 'believe,' 'expect,' 'anticipate,' 'intend,' 'estimate,' 'project' and similar expressions that do not relate solely to historical matters identify forward-looking statements.

这些前瞻性陈述基于管理层的信念和假设以及目前可用的信息。“相信”、“期望”、“预期”、“打算”、“估计”、“项目”等词以及与历史事件无关的类似表达都是前瞻性陈述。

Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to those described in our Form 10-K and other filings with the U.S.

投资者在依赖前瞻性陈述时应谨慎，因为他们受到各种风险、不确定性和其他因素的影响，这些因素可能导致实际结果与任何此类前瞻性陈述中所表达的结果存在重大差异。这些因素包括但不限于我们的表格10-K和其他提交给美国的文件中描述的因素。

Securities and Exchange Commission. All information set forth in this press release is as of the date hereof. You should consider these factors in evaluating the forward-looking statements included in this press release and not place undue reliance on such statements. We do not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by law..

证券交易委员会。本新闻稿中列出的所有信息均截至本新闻稿发布之日。在评估本新闻稿中的前瞻性声明时，您应该考虑这些因素，不要过度依赖这些声明。除非法律另有要求，否则如果情况发生变化，无论是由于新信息、未来发展还是其他原因，我们都没有义务公开提供对任何前瞻性声明的修订或更新。。

Oragenics, Inc.

Oragenics公司。

Janet Huffman, Chief Financial Officer

Janet Huffman，首席财务官

813-286-7900

813-286-7900

jhuffman@oragenics.com

jhuffman@oragenics.com